POPULATION PHARMACOMETRICS FOR ASSESSING RISK OF BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW (BRONJ)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 14 Apr 2017
Price : $35 *
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- 09 Apr 2017 Planned initiation date changed from 1 Jan 2016 to 1 Jun 2016.
- 09 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Oct 2015 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021, according to ClinicalTrials.gov record.